The case for & against
Bull & Bear analysis
Bearish
Vicarious Surgical Inc. (RBOT) is an emerging player in the medical technology sector, focusing on developing innovative robotic surgical systems, particularly a differentiated single-port surgical platform aimed at enhancing minimally invasive procedures. The company is strategically positioned within the robotic surgery market, which presents substantial growth opportunities as healthcare institutions increasingly seek to optimize surgical outcomes through advanced technologies.
Bull says
- ↑Q3 2025 OpEx fell 35% y/y to $11.5M, boosting runway.
- ↑Net loss narrowed to $11.1M ($1.86/sh) vs $17.1M year-ago.
- ↑Single-port robotic platform addresses 96% white-space in minimally invasive surgery.
- ↑Raised $5.9M via direct offering; robust QS and liquidity scores.
- ↑Targets design-freeze by year-end 2026, catalyzing clinical-trial progress.
- ↑Positive earnings revisions potential and strong liquidity underpin upside.
Bear says
- ↓Revenue down 22.9% CAGR highlights weak top-line momentum.
- ↓Q3 cash $13.4M vs projected $50M 2025 burn raises liquidity risk.
- ↓Net loss of $11.1M ($1.86/sh) and negative earnings yield signal strain.
- ↓Regulatory delays scrapped end-2025 FCU target, increasing execution uncertainty.
- ↓Competes with Intuitive and Medtronic; adoption risks amid entrenched players.
- ↓High short interest and market volatility reflect bearish factor environment.
Earnings Call · Q3 2024 · Mgmt. Guidance
Updated 07-10-2026bullish
Transcript signals
Bull points
- our unique single port platform will revolutionize surgery by enhancing patient outcomes, improving the surgical experience, and increasing the efficiency of care delivery.
- Furthermore, there is a growing base of evidence that supports single port's ability to improve surgical outcomes for patients, such as reduced blood loss, shorter hospital length of stay, and minimize pain and opioid use.
- We expect to make minor optimizations throughout this preliminary phase that will better ensure we meet all essential performance and safety standards required to treat our first clinical patient safely and confidently.
Bear points
- Adjusted net loss for the third quarter of 2024 was $17 million, equating to an adjusted net loss of $2.87 per share, as compared to an adjusted net loss of $20.4 million, or $3.95 per share, in the third quarter of 2023.
- GAAP net loss for the third quarter of 2024 was $17.1 million, equating to a net loss of $2.90 per share. This compares to a net loss of $15.7 million, or $3.04 per share, in the third quarter of 2023.
Read full transcript analysis ›